Chapter 1. Introduction
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
Chapter 2. Research Methodology
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
Chapter 3. Executive Summary
3.1. Market Snapshot
Chapter 4. Market Variables and Scope
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
Chapter 5. Market Dynamics Analysis and Trends
5.1. Market Dynamics
5.1.1. Market Drivers
5.1.2. Market Restraints
5.1.3. Market Opportunities
5.2. Porter’s Five Forces Analysis
5.2.1. Bargaining power of suppliers
5.2.2. Bargaining power of buyers
5.2.3. Threat of substitute
5.2.4. Threat of new entrants
5.2.5. Degree of competition
Chapter 6. Competitive Landscape
6.1.1. Company Market Share/Positioning Analysis
6.1.2. Key Strategies Adopted by Players
6.1.3. Vendor Landscape
6.1.3.1. List of Suppliers
6.1.3.2. List of Buyers
Chapter 7. Global Antibiotics Market, By Action Mechanism
7.1. Antibiotics Market, By Action Mechanism Type, 2020-2030
7.1.1. Cell Wall Synthesis Inhibitors
7.1.1.1. Market Revenue and Forecast (2016-2030)
7.1.2. Protein Synthesis Inhibitors
7.1.2.1. Market Revenue and Forecast (2016-2030)
7.1.3. DNA Synthesis Inhibitors
7.1.3.1. Market Revenue and Forecast (2016-2030)
7.1.4. RNA Synthesis Inhibitors
7.1.4.1. Market Revenue and Forecast (2016-2030)
7.1.5. Mycolic Acid Inhibitors
7.1.5.1. Market Revenue and Forecast (2016-2030)
7.1.6. Others
7.1.6.1. Market Revenue and Forecast (2016-2030)
Chapter 8. Global Antibiotics Market, By Drug Class
8.1. Antibiotics Market, By Drug Class, 2020-2030
8.1.1. Cephalosporin
8.1.1.1. Market Revenue and Forecast (2016-2030)
8.1.2. Penicillin
8.1.2.1. Market Revenue and Forecast (2016-2030)
8.1.3. Fluoroquinolone
8.1.3.1. Market Revenue and Forecast (2016-2030)
8.1.4. Macrolide
8.1.4.1. Market Revenue and Forecast (2016-2030)
8.1.5. Carbapenem
8.1.5.1. Market Revenue and Forecast (2016-2030)
8.1.6. Aminoglycoside
8.1.6.1. Market Revenue and Forecast (2016-2030)
8.1.7. Sulfonamide
8.1.7.1. Market Revenue and Forecast (2016-2030)
8.1.8. 7-ACA
8.1.8.1. Market Revenue and Forecast (2016-2030)
8.1.9. Others
8.1.9.1. Market Revenue and Forecast (2016-2030)
Chapter 9. Global Antibiotics Market, Regional Estimates and Trend Forecast
9.1. North America
9.1.1. Market Revenue and Forecast, By Action Mechanism (2016-2030)
9.1.2. Market Revenue and Forecast, By Drug Class (2016-2030)
9.1.3. U.S.
9.1.3.1. Market Revenue and Forecast, By Action Mechanism (2016-2030)
9.1.3.2. Market Revenue and Forecast, By Drug Class (2016-2030)
9.1.4. Rest of North America
9.1.4.1. Market Revenue and Forecast, By Action Mechanism (2016-2030)
9.1.4.2. Market Revenue and Forecast, By Drug Class (2016-2030)
9.2. Europe
9.2.1. Market Revenue and Forecast, By Action Mechanism (2016-2030)
9.2.2. Market Revenue and Forecast, By Drug Class (2016-2030)
9.2.3. UK
9.2.3.1. Market Revenue and Forecast, By Action Mechanism (2016-2030)
9.2.3.2. Market Revenue and Forecast, By Drug Class (2016-2030)
9.2.4. Germany
9.2.4.1. Market Revenue and Forecast, By Action Mechanism (2016-2030)
9.2.4.2. Market Revenue and Forecast, By Drug Class (2016-2030)
9.2.5. France
9.2.5.1. Market Revenue and Forecast, By Action Mechanism (2016-2030)
9.2.5.2. Market Revenue and Forecast, By Drug Class (2016-2030)
9.2.6. Rest of Europe
9.2.6.1. Market Revenue and Forecast, By Action Mechanism (2016-2030)
9.2.6.2. Market Revenue and Forecast, By Drug Class (2016-2030)
9.3. APAC
9.3.1. Market Revenue and Forecast, By Action Mechanism (2016-2030)
9.3.2. Market Revenue and Forecast, By Drug Class (2016-2030)
9.3.3. India
9.3.3.1. Market Revenue and Forecast, By Action Mechanism (2016-2030)
9.3.3.2. Market Revenue and Forecast, By Drug Class (2016-2030)
9.3.4. China
9.3.4.1. Market Revenue and Forecast, By Action Mechanism (2016-2030)
9.3.4.2. Market Revenue and Forecast, By Drug Class (2016-2030)
9.3.5. Japan
9.3.5.1. Market Revenue and Forecast, By Action Mechanism (2016-2030)
9.3.5.2. Market Revenue and Forecast, By Drug Class (2016-2030)
9.3.6. Rest of APAC
9.3.6.1. Market Revenue and Forecast, By Action Mechanism (2016-2030)
9.3.6.2. Market Revenue and Forecast, By Drug Class (2016-2030)
9.4. MEA
9.4.1. Market Revenue and Forecast, By Action Mechanism (2016-2030)
9.4.2. Market Revenue and Forecast, By Drug Class (2016-2030)
9.4.3. GCC
9.4.3.1. Market Revenue and Forecast, By Action Mechanism (2016-2030)
9.4.3.2. Market Revenue and Forecast, By Drug Class (2016-2030)
9.4.4. North Africa
9.4.4.1. Market Revenue and Forecast, By Action Mechanism (2016-2030)
9.4.4.2. Market Revenue and Forecast, By Drug Class (2016-2030)
9.4.5. South Africa
9.4.5.1. Market Revenue and Forecast, By Action Mechanism (2016-2030)
9.4.5.2. Market Revenue and Forecast, By Drug Class (2016-2030)
9.4.6. Rest of MEA
9.4.6.1. Market Revenue and Forecast, By Action Mechanism (2016-2030)
9.4.6.2. Market Revenue and Forecast, By Drug Class (2016-2030)
9.5. Latin America
9.5.1. Market Revenue and Forecast, By Action Mechanism (2016-2030)
9.5.2. Market Revenue and Forecast, By Drug Class (2016-2030)
9.5.3. Brazil
9.5.3.1. Market Revenue and Forecast, By Action Mechanism (2016-2030)
9.5.3.2. Market Revenue and Forecast, By Drug Class (2016-2030)
9.5.4. Rest of LATAM
9.5.4.1. Market Revenue and Forecast, By Action Mechanism (2016-2030)
9.5.4.2. Market Revenue and Forecast, By Drug Class (2016-2030)
Chapter 10. Company Profiles
10.1. Merck & Co., Inc.
10.1.1. Company Overview
10.1.2. Product Offerings
10.1.3. Financial Performance
10.1.4. Recent Initiatives
10.2. Allergan plc (AbbVie)
10.2.1. Company Overview
10.2.2. Product Offerings
10.2.3. Financial Performance
10.2.4. Recent Initiatives
10.3. GlaxoSmithKline plc.
10.3.1. Company Overview
10.3.2. Product Offerings
10.3.3. Financial Performance
10.3.4. Recent Initiatives
10.4. Pfizer Inc.
10.4.1. Company Overview
10.4.2. Product Offerings
10.4.3. Financial Performance
10.4.4. Recent Initiatives
10.5. Melinta Therapeutics
10.5.1. Company Overview
10.5.2. Product Offerings
10.5.3. Financial Performance
10.5.4. Recent Initiatives
10.6. Basilea Pharmaceutica Ltd.
10.6.1. Company Overview
10.6.2. Product Offerings
10.6.3. Financial Performance
10.6.4. Recent Initiatives
10.7. Tetraphase Pharmaceuticals
10.7.1. Company Overview
10.7.2. Product Offerings
10.7.3. Financial Performance
10.7.4. Recent Initiatives
10.8. Paratek Pharmaceuticals, Inc.
10.8.1. Company Overview
10.8.2. Product Offerings
10.8.3. Financial Performance
10.8.4. Recent Initiatives
10.9. Nabriva Therapeutics plc
10.9.1. Company Overview
10.9.2. Product Offerings
10.9.3. Financial Performance
10.9.4. Recent Initiatives
10.10. Spero Therapeutics
10.10.1. Company Overview
10.10.2. Product Offerings
10.10.3. Financial Performance
10.10.4. Recent Initiatives
Chapter 11. Research Methodology
11.1. Primary Research
11.2. Secondary Research
11.3. Assumptions
Chapter 12. Appendix
12.1. About Us
Glossary of Terms